Skip to main content

Advertisement

Table 1 BCMA-targeted CAR T clinical trials in multiple myeloma

From: Recent updates on CAR T clinical trials for multiple myeloma

Registration number (reference) Phase Dosage No. of patients Responses
NCT02215967 (49) 1 0.3–9.0 × 106 CAR+T cells/kg 12 sCR: 1; VGPR:2; PR:1; SD:8
NCT02658929 (51) 1 50–800 × 106 CAR+ T cells 33 sCR:12; CR:3; VGPR:9; PR:4; SD:4; PD:1
NCT03274219 (52) 1 150 × 106 CAR+ T cells 8 sCR: 1; VGPR: 3; PR: 2 MRD negative: 3
NCT03090659 (55) 1/2 0.07–2.1 × 106 CAR+ T cells/kg 57 CR: 39; VGPR: 3; PR: 8; MRD negative: 36; ORR: 88%
ChiCTR-ONH-17012285 (53) 1 0.21–1.52 × 106 CAR+ T cells/kg 17 sCR: 13; VGPR: 2; ORR: 88.2% NR: 1
NCT03430011 (58) 1/2 50–150 × 106 CAR+ T cells 19 sCR: 2; CR: 1; VGPR: 2; PR: 2; MR: 1
NCT03915184 (59) NA 0.5–1.8 × 108 CAR+ T cells 16 CR: 2; PR: 4; VGPR: 6 ORR: 100%
NCT03070327 (61) 1 72–818 × 106 CAR+ T cells 11 VGPR: 2; ORR: 64%
ChiCTR1800018137 (64) 1 1.0–6.0 × 106 CAR+ T cells/kg 9 CR:4; VGPR:1; PR: 4; ORR: 100%
NCT02546167 (65) 1 1–50 × 107 CAR+T cells 25 sCR: 1; CR: 1; VGPR: 5; PR: 5
NCT03288493 (67) 1 48–430 × 106 CAR+ T cells 12 sCR: 1; nCR: 1; VGPR: 1; PR: 2
NCT03338972 (69) 1 5–15 × 107 CAR+ T cells 7 ORR:100%
  1. Abbreviations: BCMA B cell maturation antigen, CAR Chimeric antigen receptor, VGPR Very good partial response, SD Stable disease, CR Complete response, PR Partial response, sCR Stringent complete response, PD Progressive disease, ORR Overall response rate, MRD Minimal residual disease, nCR near Complete response, BMPC Bone marrow plasma cells, IHC Immunohistochemistry, FC Flow cytometry, MR Minimal response, NR non-response, RRMM relapsed/refractory Multiple Myeloma, NA not available, E evaluable